Shanghai Henlius Biotech (HKG:2696) has received approval for its application for the clinical trial of pembrolizumab biosimilar HLX17 from China's National Medical Products Administration, a Monday bourse filing said.
HLX17 is intended to treat melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell cancer, and various other kinds of cancer, according to the biopharmaceutical company.
Price (HKD): $23.05, Change: $+0.050, Percent Change: +0.22%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments